Atrial fibrillation
Not yet recruitingPrevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban
Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban
- Disease:Atrial fibrillation
- Substances:ApixabanHuman Igg4 S228P Monoclonal Antibody Against Factor Xi And Activated Factor Xi
Hungary- Participants:18–64 years · 65+ years
- Substances:Apixaban
- Sponsor:Regeneron Pharmaceuticals Inc.












